1. Home
  2. BILI vs PTCT Comparison

BILI vs PTCT Comparison

Compare BILI & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bilibili Inc.

BILI

Bilibili Inc.

N/A

Current Price

$11.04

Market Cap

5.7B

Sector

Technology

ML Signal

N/A

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

N/A

Current Price

$58.29

Market Cap

5.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BILI
PTCT
Founded
2009
1998
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
5.0B
IPO Year
2017
2006

Fundamental Metrics

Financial Performance
Metric
BILI
PTCT
Price
$11.04
$58.29
Analyst Decision
Strong Buy
Buy
Analyst Count
30
15
Target Price
$24.74
★ $100.47
AVG Volume (30 Days)
★ 3.1M
934.6K
Earning Date
11-24-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 264.48
EPS
N/A
★ 0.34
Revenue
N/A
★ $264,734,000.00
Revenue This Year
$7.74
N/A
Revenue Next Year
$10.45
$8.29
P/E Ratio
★ $122.37
$177.18
Revenue Growth
N/A
★ 36.19
52 Week Low
$11.51
$58.80
52 Week High
$36.40
$90.87

Technical Indicators

Market Signals
Indicator
BILI
PTCT
Relative Strength Index (RSI) 25.29 38.39
Support Level N/A N/A
Resistance Level $19.10 $69.74
Average True Range (ATR) 0.37 2.46
MACD -0.23 -0.54
Stochastic Oscillator 0.00 1.34

Price Performance

Historical Comparison
BILI
PTCT

About BILI Bilibili Inc.

Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: